According to an article yesterday on Cancer Therapy Advisor, testing for circulating tumor cell (CTC)-based androgen receptor splice variant-7 (AR-V7) has now been validated as a prognostic test for men with castration-resistant prostate cancer (CRPC) receiving hormone therapy.
As far as we are aware, this test (which can be carried out on a simple blood sample) is still only available, as yet, through the Molecular Diagnostics Laboratory at Johns Hopkins Medical Center in Baltimore, MD.
Many might argue that the use of this test had actually been “validated” at least a couple of years ago, when the US Food and Drug Administration approved a clinical trial initiated by Tokai Pharmaceuticals. The trial was designed to test an investigational drug for the treatment of men with advanced prostate cancer who were AR-V7 positive. The test developed at Johns Hopkins was used to clearly identify men who could be entered into that trial (although, unfortunately, that trial showed that the investigational drug was not effective in the treatment of AR-V7 positive patients).